Artal Group S.A. Jounce Therapeutics, Inc. Transaction History

Artal Group S.A.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2018 May 10, 2018	SELL	$13.4 - $28.4 $2.01 Million - $4.26 Million	-150,000 Closed	0 $0
Q4 2017 Feb 09, 2018	SELL	$12.52 - $17.82 $626,000 - $891,000	-50,000 Reduced 25.0%	150,000 $1.91 Million
Q3 2017 Nov 08, 2017	BUY	$11.17 - $16.99 $2.23 Million - $3.4 Million	200,000	200,000 $3.12 Million

720K

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.